Immuron Ltd has released a press release.
Immuron Travelan continued strong sales growth
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Immuron
- Immuron Announces Travelan Clinical Trial Update
- NMRC Reports Results for Campylobacter Clinical Study
- Trading Halt
- Immuron Plans Phase 2 Trial for IMM-529 following FDA review
- Appendix 4E and Preliminary Final Report
Later from Immuron
- IMC and Calmino to treat Irritable Bowel Syndrome (IBS)
- Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)
- Immuron Travelan highest sales in history
- FY25 global sales exceed projection, up 49% on prior year
- Presenting on Emerging Growth Conference 85 Day 1 on August 20; Register to live stream
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron